Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002281 · ClinicalTrials.gov registry record · NA

A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex

A NA study of HIV Infections and Cytopenias, sponsored by Amgen.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT00002281: Completed NA study of HIV Infections and Cytopenias, sponsored by Amgen.

NCT00002281 is a NA study of HIV Infections and Cytopenias that has completed, run by Amgen. The registered enrollment target is 24 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002281, a NA study of HIV Infections and Cytopenias, has completed, sponsored by Amgen.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

To evaluate the safety, tolerance and biological activity of filgrastim (granulocyte colony-stimulating factor; G-CSF) given by daily subcutaneous (SC) injection prior to and concomitantly with erythropoietin (EPO) and zidovudine (AZT) in patients with AIDS or severe AIDS related complex (ARC). To evaluate the safety, tolerance, and biological activity of EPO given 3 times weekly by SC injection concomitantly with G-CSF and prior to and concomitantly with AZT in patients with AIDS or severe ARC. To study the safety and tolerance of 3 dose levels of AZT given to patients with AIDS or severe ARC concomitantly treated with G-CSF and EPO. To study the effect of G-CSF alone and in combination with EPO on HIV replication in vivo as measured by circulating HIV p24 antigen, plasma HIV viremia and semiquantitative HIV cocultures.

Conditions Studied

HIV Infections Cytopenias

Interventions

  • DRUG Zidovudine
  • DRUG Filgrastim
  • DRUG Epoetin alfa

Study Locations (1)

California

  • UCLA Med Ctr - Los Angeles

Trial Details

FieldValue
Enrollment Target 24 participants
Phase NA
Amgen

558 total trials

What the finished NCT00002281 record still lists

NCT00002281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.

NCT00002281 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002281 about?

NCT00002281 is a clinical study titled "A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex". To evaluate the safety, tolerance and biological activity of filgrastim (granulocyte colony-stimulating factor; G-CSF) given by daily subcutaneous (SC) injection prior to and concomitantly with erythropoietin (EPO) and zidovudine (AZT) in patients with AIDS or severe AIDS related complex (ARC). To e...

What is the current status of trial NCT00002281?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants.

What conditions does trial NCT00002281 study?

This clinical trial studies the following conditions: HIV Infections, Cytopenias.

What interventions are being tested in trial NCT00002281?

The interventions under investigation include: Zidovudine (DRUG), Filgrastim (DRUG), Epoetin alfa (DRUG).

Who is sponsoring clinical trial NCT00002281?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002281 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002281's enrollment target sits among peer trials

24 470th of 542 higher than 64 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Related registry views

Source: ClinicalTrials.gov NCT00002281, the US trial registry maintained by the National Library of Medicine. NCT00002281 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.